116 related articles for article (PubMed ID: 26599519)
1. Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach.
Marton Z; Guillon R; Krimm I; Preeti ; Rahimova R; Egron D; Jordheim LP; Aghajari N; Dumontet C; Périgaud C; Lionne C; Peyrottes S; Chaloin L
J Med Chem; 2015 Dec; 58(24):9680-96. PubMed ID: 26599519
[TBL] [Abstract][Full Text] [Related]
2. Lead optimization and biological evaluation of fragment-based cN-II inhibitors.
Guillon R; Rahimova R; Preeti ; Egron D; Rouanet S; Dumontet C; Aghajari N; Jordheim LP; Chaloin L; Peyrottes S
Eur J Med Chem; 2019 Apr; 168():28-44. PubMed ID: 30798051
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening.
Jordheim LP; Marton Z; Rhimi M; Cros-Perrial E; Lionne C; Peyrottes S; Dumontet C; Aghajari N; Chaloin L
Biochem Pharmacol; 2013 Feb; 85(4):497-506. PubMed ID: 23220537
[TBL] [Abstract][Full Text] [Related]
4. 4-Aminopyridine based amide derivatives as dual inhibitors of tissue non-specific alkaline phosphatase and ecto-5'-nucleotidase with potential anticancer activity.
Hassan S; Ejaz SA; Saeed A; Shehzad M; Ullah Khan S; Lecka J; Sévigny J; Shabir G; Iqbal J
Bioorg Chem; 2018 Feb; 76():237-248. PubMed ID: 29197225
[TBL] [Abstract][Full Text] [Related]
5. Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.
Iqbal J; Saeed A; Raza R; Matin A; Hameed A; Furtmann N; Lecka J; Sévigny J; Bajorath J
Eur J Med Chem; 2013; 70():685-91. PubMed ID: 24215819
[TBL] [Abstract][Full Text] [Related]
6. The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor.
Cividini F; Pesi R; Chaloin L; Allegrini S; Camici M; Cros-Perrial E; Dumontet C; Jordheim LP; Tozzi MG
Biochem Pharmacol; 2015 Mar; 94(2):63-8. PubMed ID: 25656700
[TBL] [Abstract][Full Text] [Related]
7. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
[TBL] [Abstract][Full Text] [Related]
8. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure--activity relationship (SAR) studies of imidazo[4,5-b]pyridine derived purine isosteres and their potential as cytotoxic agents.
Sajith AM; Abdul Khader KK; Joshi N; Reddy MN; Syed Ali Padusha M; Nagaswarupa HP; Nibin Joy M; Bodke YD; Karuvalam RP; Banerjee R; Muralidharan A; Rajendra P
Eur J Med Chem; 2015 Jan; 89():21-31. PubMed ID: 25462222
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, in vitro anticancer evaluation and in silico studies of novel imidazo[2,1-b]thiazole derivatives bearing pyrazole moieties.
Ali AR; El-Bendary ER; Ghaly MA; Shehata IA
Eur J Med Chem; 2014 Mar; 75():492-500. PubMed ID: 24576591
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of β-hydroxyphosphonate nucleoside analogues as cytosolic 5'-nucleotidase II potential inhibitors: synthesis, in vitro evaluation and molecular modeling studies.
Meurillon M; Marton Z; Hospital A; Jordheim LP; Béjaud J; Lionne C; Dumontet C; Périgaud C; Chaloin L; Peyrottes S
Eur J Med Chem; 2014 Apr; 77():18-37. PubMed ID: 24607586
[TBL] [Abstract][Full Text] [Related]
12. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the inhibition of cytosolic 5'-nucleotidase II (cN-II) by ribonucleoside 5'-monophosphate analogues.
Gallier F; Lallemand P; Meurillon M; Jordheim LP; Dumontet C; Périgaud C; Lionne C; Peyrottes S; Chaloin L
PLoS Comput Biol; 2011 Dec; 7(12):e1002295. PubMed ID: 22174667
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.
Unzue A; Dong J; Lafleur K; Zhao H; Frugier E; Caflisch A; Nevado C
J Med Chem; 2014 Aug; 57(15):6834-44. PubMed ID: 25076195
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and docking studies of 4-amino-tetrahydroquinazolino[3,2-e]purine derivatives.
Verones V; Flouquet N; Farce A; Carato P; Leonce S; Pfeiffer B; Berthelot P; Lebegue N
Eur J Med Chem; 2010 Dec; 45(12):5678-84. PubMed ID: 20884092
[TBL] [Abstract][Full Text] [Related]
16. Ectonucleotidase Inhibitory and Redox Activity of Imidazole-Based Organic Salts and Ionic Liquids.
Boldescu V; Sucman N; Hassan S; Iqbal J; Neamtu M; Lecka J; Sévigny J; Prodius D; Macaev F
ChemMedChem; 2018 Nov; 13(21):2297-2304. PubMed ID: 30192439
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
18. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of molecular model-based discovery of ecto-5'-nucleotidase inhibitors on the basis of X-ray structures.
Furtmann N; Bajorath J
Bioorg Med Chem; 2013 Nov; 21(21):6616-22. PubMed ID: 24012379
[TBL] [Abstract][Full Text] [Related]
20. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
